Values as of: 2025-01-11
COMMON STOCK | Biotechnology |
Last Closing
USD 5.27Change
0.00 (0.00)%Market Cap
USD 0.56BVolume
N/AAnalyst Target
N/AVerdict
Verdict
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Company Website : https://www.oxb.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ARGNF | argenx SE |
N/A |
USD 39.01B |
| UCBJF | UCB SA |
N/A |
USD 37.94B |
| UCBJY | UCB SA ADR |
N/A |
USD 37.34B |
| GNMSF | Genmab A/S |
N/A |
USD 13.64B |
| WXIBF | WuXi Biologics |
N/A |
USD 8.99B |
| WXXWY | WuXi Biologics (Cayman) Inc |
N/A |
USD 8.93B |
| IVBIY | IVBIY |
N/A |
USD 7.80B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 7.48B |
| ZLDPF | Zealand Pharma A/S |
N/A |
USD 7.14B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 6.89B |
N/A
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -2.32% | 38% | F | 36% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -2.32% | 38% | F | 36% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 95.91% | 86% | B+ | 92% | A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 95.91% | 86% | B+ | 91% | A- | ||
| Trailing 5 Years | |||||||
| Capital Gain | -41.58% | 70% | C- | 43% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -41.58% | 69% | C- | 40% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -1.31% | 45% | F | 35% | F | ||
| Dividend Return | -1.31% | 45% | F | 31% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 61.70% | 60% | D- | 45% | F | ||
| Risk Adjusted Return | -2.13% | 46% | F | 32% | F | ||
| Market Capitalization | 0.56B | 88% | B+ | 69% | C- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
